ZYBT· Health Care› Drug Manufacturers - Specialty & Generic

Zhengye Biotechnology Holding Limited Class A

Stage 3 · Topping · week 3

As of Oct 22, 2026, Zhengye Biotechnology Holding is in Stage 3, the topping phase, now in week 3 (since Oct 6, 2026). It closed at $1.46, 81.8% below its 52-week high and above its 200-day average, which is falling.

Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. More about the company

$1.46

+0.41% today

$69.2M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Accelerating ⇈

Edge

—

Is ZYBT early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2025-01-07 → 2026-10-22

S? 41w

S4 27w

2025-01-072026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 41w → S4 27w → S1 7w → S4 4w → S1 4w → S2 7w → S3 2w current

Total tracked: 93 weeks across 7 stage runs.

ZYBT among Drug Manufacturers - Specialty & Generic57th of 84 by relative strength

All 84 →

Stocks in Drug Manufacturers - Specialty & Generic ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	CPIXCumberland Pharmaceuticals Inc.	Stage 2 · wk 23	98	+6.8%
2	ETONEton Pharmaceuticals, Inc.	Stage 2 · wk 30	97	−10.1%
3	ANIKAnika Therapeutics Inc.	Stage 2 · wk 15	96	+3.5%
4	IRWDIronwood Pharmaceuticals, Inc. Class A	Stage 3 · wk 3	96	−16.4%
5	TEVATeva Pharmaceutical Industries Limited	Stage 2 · wk 9	95	+3.1%
6	AMRXAmneal Pharmaceuticals, Inc. Class A	Stage 2 · wk 19	95	+5.9%
7	KNSAKiniksa Pharmaceuticals International, plc Class A	Stage 2 · wk 73	95	+6.2%
8	AMLXAmylyx Pharmaceuticals, Inc.	Stage 2 · wk 15	93	−6.6%
…57	ZYBTZhengye Biotechnology Holding Limited Class A	Stage 3 · wk 3	27	+6.6%

vs 52W High

-81.8%

$0.65 lo$8.01 hi

81.8% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 3

1w13w26w

Week 3, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

27.2%

200 DMA: $1.15 · sloping down

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.13x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↑ ⇈

Short-term trend rising strongly, and accelerating

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+6.6%

-15.6%

+58.7%

YTD

+29.2%

-41.8%

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S3

Wk 3 · Vol 0.13x

2026-10-21S3

Wk 3 · Vol 0.06x

2026-10-20S3

Wk 3 · Vol 0.02x

2026-10-19S3

Wk 2 · Vol 0.04x

2026-10-16S3

Wk 2 · Vol 0.07x

2026-10-15S3

Wk 2 · Vol 0.03x

2026-10-14S3

Wk 2 · Vol 0.10x

2026-10-13S3

Wk 2 · Vol 0.17x

2026-10-12S3

Wk 1 · Vol 1.18x

2026-10-09S3

Wk 1 · Vol 16.35x

2026-10-08S3

Wk 1 · Vol 0.01x

2026-10-07S3

Wk 1 · Vol 0.02x

Moving averages & range

50 DMA

$1.50

200 DMA

$1.15

52W High

$8.01

52W Low

$0.65

5D Low

$1.40

Resistance levels (recent highs)

20d High

$1.73

60d High

$2.36

120d High

$8.01

250d High

$8.01

Next resistance

+18.5%

to 20d High

ROE

-25.2%

Profit margin -60.0%

Dividend Yield

0.00%

P/B 1.8

Zhengye Biotechnology Holding: quick answers

What stage is Zhengye Biotechnology Holding in?

As of Oct 22, 2026, Zhengye Biotechnology Holding (ZYBT) is in Stage 3, the topping phase. It entered Stage 3 on Oct 6, 2026 and is in week 3. What the four stages mean

Is Zhengye Biotechnology Holding in an uptrend?

Its uptrend has stalled. Zhengye Biotechnology Holding is in Stage 3, the topping phase that follows an advance. It trades 27.2% above its 200-day average, which is falling.

How far is Zhengye Biotechnology Holding from its 52-week high?

Zhengye Biotechnology Holding closed at $1.46 on Oct 22, 2026, 81.8% below its 52-week high of $8.01. Its 52-week low is $0.65.

How has Zhengye Biotechnology Holding performed over the past year?

As of Oct 22, 2026, Zhengye Biotechnology Holding is down 41.8% over the past year and up 29.2% so far in 2026.

Which sector and industry is Zhengye Biotechnology Holding in?

Zhengye Biotechnology Holding is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.

About this companyHealth Care· Drug Manufacturers - Specialty & Generic

Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine. It also develops vaccines for household animals, including rabies vaccine and Strain Flury LEP for dogs. In addition, the company exports its products to Vietnam, Pakistan, and Egypt. It serves direct-end customers, including livestock farmers and local governments; and domestic distributors and exporting distributors. The company was incorporated in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.